Palisade Bio (PALI) Virtual Investor Closing Bell Series summary

Corporate overview and strategy

• Focus on advancing early-stage drugs for immunology and inflammatory diseases, especially those with a fibrotic component.

• Lead program is a PDE4 inhibitor prodrug (PALI-2108) targeting ulcerative colitis and Crohn's disease, with phase I human studies starting soon.

• Pipeline includes two drugs based on the same molecule, with preclinical studies nearing completion.

• Strategy is to advance drugs through phase 2a/2b and then partner with big pharma for commercialization.

• Recent big pharma acquisitions in the space highlight strong market interest, even for preclinical assets.

Scientific and clinical highlights

• PALI-2108 is a locally-activated oral prodrug designed to minimize systemic side effects and improve efficacy.

• Addresses significant unmet need in ulcerative colitis, where current remission rates are low and many patients fail first-line therapies.

• Demonstrated proof of concept and efficacy in gold-standard preclinical models, with improved disease activity and colon length.

• Precision medicine approach uses transcriptomics and machine learning to identify patients most likely to respond.

• Phase I study will include biomarker-driven patient selection, with top-line data expected in the first half of 2025.

Market opportunity and differentiation

• Ulcerative colitis market exceeds $7 billion, projected to reach $10 billion in 4–5 years; majority of moderate to severe patients have elevated PDE4 activity.

• PALI-2108 targets 70–80% of this market, offering a differentiated oral therapy without black box warnings.

• PDE4 inhibitors have shown efficacy, but systemic versions are limited by side effects; local delivery aims to overcome this.

• Intellectual property protection extends to 2042, with additional regulatory exclusivity expected.

• Potential applications include fibrostenotic Crohn's disease and other fibro-inflammatory conditions like IPF.